TNF and inflammatory bowel disease: The 5-aminosalicylic acids (5-ASAs) exert their therapeutic effects in IBD through multiple mechanisms, including the inhibition of proinflammatory cytokines such as TNF-a and interleukins, suppression of leukocyte chemotaxis, and scavenging of free radicals.